An international working group was formed to standardize response criteria for therapy of myelodysplastic syndromes (MDS). Disease progression or relapse may occur after an initial improvement in hematologic parameters. The authors are from multiple institutions in Europe and the United States.


Patient selection: hematologic improvement after cytotoxic therapy for MDS


Criteria for progression or relapse - one or more of the following:

(1) >= 50% decrease in absolute neutrophil count from maximum response

(2) >= 50% decrease in platelet count from maximum response

(3) reduction in hemoglobin concentration by >= 2.0 g/dL

(4) red blood cell transfusion dependence

(5) platelet transfusion dependence



(1) Gastrointestinal bleeding or other disorder that can explain the findings.

(2) Chemotherapy effect.


To read more or access our algorithms and calculators, please log in or register.